LEXX (Lexaria Bioscience) Cyclically Adjusted Book per Share: $1.11 (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LEXX Lexaria Bioscience Corp LEXX
22 GF Score
Price $0.54
GF Value $0.37
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Lexaria Bioscience Cyclically Adjusted Book per Share?

Lexaria Bioscience LEXX +3.69% 22 Cyclically Adjusted Book per Share is $1.11 as of May. 2026. GuruFocus rates LEXX with a GF Score™ of 22/100 and a GF Value™ of $0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Lexaria Bioscience's adjusted book value per share for the three months ended in May. 2026 was $0.191. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.11 for the trailing ten years ended in May. 2026.

During the past 12 months, Lexaria Bioscience's average Cyclically Adjusted Book Growth Rate was 1.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -16.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -14.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -17.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Lexaria Bioscience was -13.10% per year. The lowest was -24.60% per year. And the median was -17.65% per year.

As of today (2026-07-28), Lexaria Bioscience's current stock price is $0.5435. Lexaria Bioscience's Cyclically Adjusted Book per Share for the quarter that ended in May. 2026 was $1.11. Lexaria Bioscience's Cyclically Adjusted PB Ratio of today is 0.49.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lexaria Bioscience was 16.10. The lowest was 0.45. And the median was 2.22.


Lexaria Bioscience  (NAS:LEXX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Lexaria Bioscience's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.5435/1.11
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lexaria Bioscience was 16.10. The lowest was 0.45. And the median was 2.22.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Lexaria Bioscience Cyclically Adjusted Book per Share Related Terms


Lexaria Bioscience Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Lexaria Bioscience's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexaria Bioscience Cyclically Adjusted Book per Share Chart

Lexaria Bioscience Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.03 1.82 1.47 1.13 1.08

Lexaria Bioscience Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.09 1.08 1.08 1.08 1.11

LEXX vs CTXR, PTN, HIND: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Lexaria Bioscience's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexaria Bioscience Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Cyclically Adjusted PB Ratio falls into.


LEXX
22GF Score
Lexaria Bioscience Corp LEXX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexaria Bioscience Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lexaria Bioscience's adjusted Book Value per Share data for the three months ended in May. 2026 was:

Adj_Book= Book Value per Share /CPI of May. 2026 (Change)*Current CPI (May. 2026)
=0.191/134.0005*134.0005
=0.191

Current CPI (May. 2026) = 134.0005.

Lexaria Bioscience Quarterly Data

Book Value per Share CPI Adj_Book
201608 0.156 101.686 0.206
201611 0.440 101.607 0.580
201702 0.368 102.476 0.481
201705 1.472 103.108 1.913
201708 1.327 103.108 1.725
201711 1.038 103.740 1.341
201802 1.170 104.688 1.498
201805 1.093 105.399 1.390
201808 0.948 106.031 1.198
201811 1.328 105.478 1.687
201902 1.069 106.268 1.348
201905 1.216 107.927 1.510
201908 0.907 108.085 1.124
201911 0.940 107.769 1.169
202002 0.699 108.559 0.863
202005 1.067 107.532 1.330
202008 0.841 108.243 1.041
202011 0.626 108.796 0.771
202102 2.306 109.745 2.816
202105 2.027 111.404 2.438
202108 2.316 112.668 2.755
202111 2.040 113.932 2.399
202202 1.925 115.986 2.224
202205 1.543 120.016 1.723
202208 1.336 120.569 1.485
202211 1.052 121.675 1.159
202302 0.836 122.070 0.918
202305 0.543 124.045 0.587
202308 0.376 125.389 0.402
202311 0.363 125.468 0.388
202402 0.526 125.468 0.562
202405 0.640 127.601 0.672
202408 0.508 127.838 0.532
202411 0.560 127.838 0.587
202502 0.407 128.786 0.423
202505 0.284 129.813 0.293
202508 0.153 130.208 0.157
202511 0.221 130.682 0.227
202602 0.265 131.077 0.271
202605 0.191 134.001 0.191

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $1.11 mean?
Lexaria Bioscience (LEXX) has a Cyclically Adjusted Book per Share of $1.11 as of May. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Lexaria Bioscience and its competitors.
Is Lexaria Bioscience's Cyclically Adjusted Book per Share too high?
Lexaria Bioscience's current Cyclically Adjusted Book per Share is $1.11. Overall, Lexaria Bioscience has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's Cyclically Adjusted Book per Share compare to CTXR and PTN?
Lexaria Bioscience's Cyclically Adjusted Book per Share of $1.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Lexaria Bioscience and its competitors. Lexaria Bioscience's current Cyclically Adjusted Book per Share is $1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $0.54 — trading 46.9% above its estimated fair value. The current Cyclically Adjusted Book per Share is $1.11. Lexaria Bioscience's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current Cyclically Adjusted Book per Share is $1.11 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lexaria Bioscience (LEXX) Overvalued in 2026?

Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be overvalued. The current stock price of $0.54 is trading 46.9% above its estimated GF Value™ of $0.37. GuruFocus considers Lexaria Bioscience to be Significantly Overvalued.

Key valuation signals for LEXX:

  • Cyclically Adjusted Book per Share: $1.11
  • GF Value™: $0.37 vs. price of $0.54 (46.9% above fair value)
  • GF Score™: 22/100 with 4 warning signs

No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lexaria Bioscience Business Description

Address 740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
22GF Score

Get the complete analysis for LEXX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.54
Price
$0.37
GF Value